Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.

[1]  B. Conway,et al.  Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. , 2017, The International journal on drug policy.

[2]  M. Carr,et al.  The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors , 2016, PloS one.

[3]  P. Easterbrook.  Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. , 2016, Journal of hepatology.

[4]  Kathy Petoumenos,et al.  Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study , 2016, Hepatology.

[5]  A. Aghemo,et al.  Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  M. Manns,et al.  Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. , 2016, Journal of hepatology.

[7]  F. Wiesmann,et al.  Significance of HCV RNA monitoring in the era of new potent therapies , 2016, Expert review of anti-infective therapy.

[8]  M. N. Kim,et al.  Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C , 2016, Journal of Korean medical science.

[9]  J. M. Freiman,et al.  Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection , 2016, Annals of Internal Medicine.

[10]  J. Pawlotsky,et al.  Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen , 2016, Antiviral therapy.

[11]  G. Dawson,et al.  Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection , 2015, Journal of Clinical Microbiology.

[12]  M. Proschan,et al.  Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. , 2015, Annals of internal medicine.

[13]  A. Hill,et al.  Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment , 2015, Current opinion in HIV and AIDS.

[14]  P. Paci,et al.  The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection. , 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  S. Kassim,et al.  The accuracy and cost‐effectiveness of hepatitis C core antigen assay in the monitoring of anti‐viral therapy in patients with chronic hepatitis C genotype 4 , 2015, Alimentary pharmacology & therapeutics.

[16]  G. Dore,et al.  The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis , 2015, PloS one.

[17]  J. Joy,et al.  Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir , 2015, Journal of Clinical Microbiology.

[18]  W. Hall,et al.  Hepatitis C Virus Core Mutations Associated with False-Negative Serological Results for Genotype 3a Core Antigen , 2015, Journal of Clinical Microbiology.

[19]  J. Ward,et al.  Performance of ARCHITECT HCV core antigen test with specimens from US plasma donors and injecting drug users. , 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  J. Pawlotsky,et al.  Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. , 2015, Journal of virological methods.

[21]  H. Masur,et al.  Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  F. Cresswell,et al.  Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  F. Lehner,et al.  Hepatitis C virus core antigen testing in liver and kidney transplant recipients , 2014, Journal of viral hepatitis.

[24]  M. Capobianchi,et al.  HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes , 2014, BMC Infectious Diseases.

[25]  G. Dore,et al.  Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.

[26]  M. Thursz,et al.  Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. , 2013, Future virology.

[27]  A. Georgiou,et al.  Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay , 2013, Annals of gastroenterology.

[28]  R. Tedder,et al.  Therapy‐induced clearance of HCV core antigen from plasma predicts an end of treatment viral response , 2013, Journal of viral hepatitis.

[29]  T. Wakita,et al.  Japanese Reference Panel of Blood Specimens for Evaluation of Hepatitis C Virus RNA and Core Antigen Quantitative Assays , 2012, Journal of Clinical Microbiology.

[30]  C. Galli,et al.  Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[31]  N. Hilzenrat,et al.  Use of Sequence Analysis of the NS5B Region for Routine Genotyping of Hepatitis C Virus with Reference to C/E1 and 5′ Untranslated Region Sequences , 2007, Journal of Clinical Microbiology.

[32]  D. Cooper,et al.  Hepatitis C Virus Core Mutations Reduce the Sensitivity of a Fluorescence Enzyme Immunoassay , 2000, Journal of Clinical Microbiology.

[33]  S. Mishiro,et al.  Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts. , 1992, The Journal of general virology.

[34]  Global Hepatitis Programme.  Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version, April 2016. , 2016 .